This content is machine translated Alternative to insulin and GLP1 From the β-cell to the center: the versatile role of amylin Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity...… CME-Test
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 6 min This content is machine translated Obesity as a chronic disease: an interdisciplinary perspective Neurobiological mechanisms of obesity A high-fat and high-sugar diet affects both the homeostatic hunger and satiety signals in the hypothalamus and the hedonic reward system, leading to persistent hunger and a strong craving for...…
View Post 11 min This content is machine translated Alternative to insulin and GLP1 From the β-cell to the center: the versatile role of amylin Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity...… CME-Test
View Post 2 min This content is machine translated "Swiss Health Care Atlas" New indicator: medication for weight regulation The healthcare atlas compiled under the auspices of Obsan documents and visualizes the frequency of medical treatments and diagnoses between cantons, regions, age groups and over time. This provides a...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
View Post 3 min This content is machine translated Adherence of GLP1-RA Half of patients discontinue treatment within a year GLP1 receptor agonists have revolutionized the treatment of obesity, but their effectiveness depends on long-term and continuous use. However, data from Danish health registries presented at EASD 2025 show that...…
View Post 6 min This content is machine translated Obesity in the family practice Aim for realistic goals and avoid apportioning blame Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the...…
View Post 6 min This content is machine translated DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline Stroke prevention for atrial fibrillation 2025 Atrial fibrillation is the most important treatable risk factor for ischemic strokes in 2025 – and at the same time an area where precision makes all the difference. The major...…
View Post 12 min This content is machine translated Doing sport without fear or risk Doing sport without fear or risk One of the most common chronic diseases in children is type 1 diabetes mellitus (T1D), which is classified as an autoimmune disease and is caused by the destruction of insulin-producing...… CME-Test
View Post 4 min This content is machine translated Obesity Extent of weight reduction is prognostically relevant According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases. Obesity-related multimorbidity is...…
